Affordable Access

A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone.

Authors
Type
Published Article
Journal
Cancer
Publication Date
Volume
94
Issue
6
Pages
1654–1660
Identifiers
PMID: 11920525
Source
Medline
License
Unknown

Abstract

The addition of strontium-89 to the regimen of EMP and vinblastine can be delivered safely and in repeated doses, provides effective palliation, and may decrease the need for future radiation therapy. A randomized trial is necessary to quantify these effects.

Statistics

Seen <100 times